Treatment Outcomes of Paclitaxel for Refractory or Recurrent Epithelial Ovarian Cancer Patients in Thailand

Pitakkarnkul, Supakorn; Tangjitgamol, Siriwan; Srijaipracharoen, Sunamchok; Manusirivithaya, Sumonmal; Pataradool, Kamol; Prutthiphongsit, Watchara; Khunnarong, Jakkapan; Thavaramara, Thaovalai

doi:10.7314/apjcp.2013.14.4.2421

Cited by 11 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The poor ratio of survival is primarily attribute to lacking of specific symptoms and effective methods for the early detection in ovarian cancer patients (Vaughan et al, 2011). In addition, the development of multidrug resistances also leads to the failure in treatment of ovarian cancer (Thigpen et al, 2011;Pitakkarnkul et al, 2013). Thus, identification of molecular markers for prognosis is important for improving therapeutic methods and extending survival of ovarian cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of TRPM7 is Associated with Poor Prognosis in Human Ovarian Carcinoma

Wang¹,

Xiao²,

Luo³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The melastatin-related transient receptor potential 7 channel (TRPM7) is a nonselective cation channel that has been shown to promote tumor metastasis and progression. In this study, we determined the expression of TRPM7 in ovarian carcinomas and investigated its possible prognostic value. Materials and Methods: Samples were collected from 138 patients with ovarian cancer. Expression of TRPM7 was assessed by real-time PCR and immunohistochemistry, expressed with reference to an established scoring system and related to clinical pathological factors. Kaplan-Meier survival analysis was applied to estimate disease-free survival (DFS) and overall survival (OS). Univariate and multivariate cox regression analyses were performed to correlate TRPM7 expression levels with DFS and OS. Results: TRPM7 was highly expressed in ovarian carcinoma and significantly associated with decreased disease-free survival (DFS: median 20 months vs. 42 months, P=0.0002) and overall survival (OS: median 27 months vs. 46 months, P<0.001). Conclusion: Overexpression of TRPM7 expression is significantly associated with poor prognosis in patients with ovarian cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Overexpression of TRPM7 is Associated with Poor Prognosis in Human Ovarian Carcinoma

Wang¹,

Xiao²,

Luo³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Even if using the relatively sensitive drug, such as gemcitabine, doxorubicin, tunicamycin and ifosfamide, the clinical remission rate is only about 10%-20% (Hiss et al, 2007;Chumworathayi, 2013;Pitakkarnkul et al, 2013;Su et al, 2013). Because this group of patients have treated with multiple cycles of chemotherapy, causing hematological and non hematological toxicity accumulation, we chosed only single gemcitabine combined with 125 I-seed implantation treatment as the therapy for patients.…”

Section: Adverse Reactionsmentioning

confidence: 99%

Efficacy of Permanent Iodine-125 Seed Implants and Gemcitabine Chemotherapy in Patients with Platinum-Resistant Recurrent Ovarian Carcinoma

Yang

Liu²,

Xu³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The aim of this study was to explore the efficacy and adverse reactions of CT-guided radioactive 125I-seed implantation treatment combined with chemotherapy for platinum-resistant recurrent ovarian carcinoma. Materials and Methods: From September 2010 to December 2012, 23 patients with platinum-resistant recurrent ovarian carcinoma were enrolled. All the patients refused, could not bear, or were not suitable for surgery. They all had no more than 3 lesions, which were detected and could also be measured by CT. All were clarified as single-lesion or multiple-lesion groups. A total of 41 lesions underwent implantation of from 8 to 106 125I seeds (median=43). Multi-plane implanting was adopted and 125I-seeds of (0.4-0.7)mCi were placed at intervals of (0.5-1.0) cm. After implantation treatment, all patients underwent 4 cycles of chemotherapy with gemcitabine 800 mg/m2 (days 1, 8 and 15). Results: The outcome was evaluated with CT 3 weeks and every 3 months after implantation treatment. After 6 months, the volume of 32 out of 41 lesions (78.0%) was reduced at least 30%, within which 9 lesions completely disappeared(22.0%). Complete response was observed in 7 cases (30.4%), with a partial response in 4 cases (17.4%),4 cases stable(17.4%)and 8 cases showing progression (34.8%). The total clinical remission rate was 47.8% (11/23). The clinical remission rate was 77.8% (7/9) in the single-lesion group and 28.6% (4/14) in the multiple-lesion group with a significant difference between the two(P=0.036). The common side effects observed were mild gastrointestinal reactions. Conclusions: 125I-seed implantation combined with chemotherapy applies an effective way in the treatment of platinum-resistant recurrent ovarian epithelial carcinoma with the advantages of high local control rates, good short-term effects, little trauma and less side effects.

show abstract

“…At present, paclitaxel is clinically used as the firstline treatment for breast cancer, lung cancer, esophageal cancer, colon cancer, lymphoma, acute leukemia, melanin, ovarian cancer and gastric cancer (Pitakkarnkul et al, 2013;Jianmin et al, 2014;Tanaka et al, 2014;Feng et al, 2015;Langer et al, 2015). However, it is hard to be absorbed by taking orally due to its physicochemical property, such as poor water solubility, so it is mostly…”

Section: Introductionmentioning

confidence: 99%

Effect of Paclitaxel-loaded Nanoparticles on the Viability of Human Hepatocellular Carcinoma HepG2 Cells

Hou

Zhao²,

Zhang³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Treatment Outcomes of Paclitaxel for Refractory or Recurrent Epithelial Ovarian Cancer Patients in Thailand

Cited by 11 publications

References 39 publications

Overexpression of TRPM7 is Associated with Poor Prognosis in Human Ovarian Carcinoma

Overexpression of TRPM7 is Associated with Poor Prognosis in Human Ovarian Carcinoma

Efficacy of Permanent Iodine-125 Seed Implants and Gemcitabine Chemotherapy in Patients with Platinum-Resistant Recurrent Ovarian Carcinoma

Effect of Paclitaxel-loaded Nanoparticles on the Viability of Human Hepatocellular Carcinoma HepG2 Cells

Contact Info

Product

Resources

About